HK1207639A1 - 作為 受體活性調節劑的乙炔基衍生物 - Google Patents

作為 受體活性調節劑的乙炔基衍生物

Info

Publication number
HK1207639A1
HK1207639A1 HK15108283.2A HK15108283A HK1207639A1 HK 1207639 A1 HK1207639 A1 HK 1207639A1 HK 15108283 A HK15108283 A HK 15108283A HK 1207639 A1 HK1207639 A1 HK 1207639A1
Authority
HK
Hong Kong
Prior art keywords
mglur5
modulators
receptor activity
ethynyl derivatives
ethynyl
Prior art date
Application number
HK15108283.2A
Other languages
English (en)
Inventor
喬治．耶施克
洛塔爾．林德曼
安東尼奧．里奇
丹尼爾．呂厄
海因茨．施塔德勒
埃里克．維埃拉
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1207639A1 publication Critical patent/HK1207639A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK15108283.2A 2012-10-18 2015-08-26 作為 受體活性調節劑的乙炔基衍生物 HK1207639A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12188940 2012-10-18
PCT/EP2013/071500 WO2014060398A1 (en) 2012-10-18 2013-10-15 Ethynyl derivatives as modulators of mglur5 receptor activity

Publications (1)

Publication Number Publication Date
HK1207639A1 true HK1207639A1 (zh) 2016-02-05

Family

ID=47049067

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108283.2A HK1207639A1 (zh) 2012-10-18 2015-08-26 作為 受體活性調節劑的乙炔基衍生物

Country Status (27)

Country Link
US (1) US9227959B2 (zh)
EP (1) EP2909180B1 (zh)
JP (1) JP5989250B2 (zh)
KR (1) KR101684816B1 (zh)
CN (1) CN104718192B (zh)
AR (1) AR093042A1 (zh)
AU (1) AU2013333988B2 (zh)
BR (1) BR112015006454A8 (zh)
CA (1) CA2882520A1 (zh)
CL (1) CL2015000891A1 (zh)
CO (1) CO7200248A2 (zh)
CR (1) CR20150144A (zh)
EA (1) EA025667B1 (zh)
ES (1) ES2599553T3 (zh)
HK (1) HK1207639A1 (zh)
IL (1) IL237380A (zh)
MA (1) MA38012B1 (zh)
MX (1) MX2015004898A (zh)
MY (1) MY168937A (zh)
NZ (1) NZ705144A (zh)
PE (1) PE20150629A1 (zh)
PH (1) PH12015500398A1 (zh)
SG (1) SG11201501392TA (zh)
TW (1) TWI490208B (zh)
UA (1) UA114529C2 (zh)
WO (1) WO2014060398A1 (zh)
ZA (1) ZA201500856B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703537A (en) * 2012-10-18 2018-06-29 Hoffmann La Roche Ethynyl derivatives
JP6603334B2 (ja) 2015-06-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー エチニル誘導体
EP3353161B1 (en) * 2015-09-25 2021-07-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Triazole derivatives as p2y14 receptor antagonists
WO2019110703A1 (en) 2017-12-08 2019-06-13 Boehringer Ingelheim International Gmbh Imidazopyridine derivatives and the use thereof as medicament
DK3867244T3 (da) 2018-10-17 2023-05-01 Boehringer Ingelheim Int 4-pyrazin-2-ylmethylmorfolinderivater og anvendelse deraf som lægemiddel
EP3866854B1 (en) 2018-10-17 2022-08-10 Boehringer Ingelheim International GmbH 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
WO2020079040A1 (en) * 2018-10-17 2020-04-23 Boehringer Ingelheim International Gmbh 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
TW202112378A (zh) 2019-06-04 2021-04-01 德商百靈佳殷格翰國際股份有限公司 嘌呤衍生物及其作為藥物之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
CA2689282A1 (en) * 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors

Also Published As

Publication number Publication date
PE20150629A1 (es) 2015-05-11
JP5989250B2 (ja) 2016-09-07
KR20150055044A (ko) 2015-05-20
BR112015006454A2 (pt) 2017-07-04
PH12015500398B1 (en) 2015-04-27
EP2909180B1 (en) 2016-10-05
EA201590699A1 (ru) 2015-07-30
SG11201501392TA (en) 2015-05-28
ES2599553T3 (es) 2017-02-02
BR112015006454A8 (pt) 2019-08-20
CO7200248A2 (es) 2015-02-27
MX2015004898A (es) 2015-07-21
CL2015000891A1 (es) 2015-09-11
AU2013333988A1 (en) 2015-02-26
WO2014060398A1 (en) 2014-04-24
IL237380A (en) 2017-02-28
TWI490208B (zh) 2015-07-01
CA2882520A1 (en) 2014-04-24
NZ705144A (en) 2018-09-28
ZA201500856B (en) 2016-08-31
KR101684816B1 (ko) 2016-12-20
CN104718192B (zh) 2016-08-31
AU2013333988B2 (en) 2017-03-09
MA38012A1 (fr) 2016-05-31
EA025667B1 (ru) 2017-01-30
PH12015500398A1 (en) 2015-04-27
JP2015531392A (ja) 2015-11-02
EP2909180A1 (en) 2015-08-26
MY168937A (en) 2019-01-10
UA114529C2 (uk) 2017-06-26
US9227959B2 (en) 2016-01-05
US20150225385A1 (en) 2015-08-13
IL237380A0 (en) 2015-04-30
AR093042A1 (es) 2015-05-13
TW201420571A (zh) 2014-06-01
MA38012B1 (fr) 2016-12-30
CN104718192A (zh) 2015-06-17
CR20150144A (es) 2015-04-30

Similar Documents

Publication Publication Date Title
HK1198168A1 (zh) 用作激酶活性調節劑的氨基嘧啶衍生物
HK1207639A1 (zh) 作為 受體活性調節劑的乙炔基衍生物
HRP20181596T1 (hr) Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora
HK1195298A1 (zh) 作為 變構調節劑的乙炔基衍生物
HK1191330A1 (zh) 作為 的正變構調節劑的乙炔基衍生物
HK1206715A1 (zh) 作爲 受體活性的調節劑的乙炔基衍生物
HK1208032A1 (zh) 作為 受體活性調節劑的乙炔基衍生物
PT3345899T (pt) Derivados de benzofurano-2-sulfonamida como moduladores dos receptores de quimioquinas
ZA201403502B (en) Nicotinic receptor non-competitive modulators